Companion diagnostic tool for mutant p53 reactivating compounds
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
Core Innovation
The invention provides a method of treating a subject suffering from cancer having a p53-deactivating mutation in a TP53 gene that encodes a p53 mutant protein. Before treatment, the subject is determined to have the mutation based on an assay performed on a biological sample. The method comprises administering a therapeutically effective amount of one of three specified indole-based compounds, or a pharmaceutically acceptable salt thereof.
The disclosed compounds bind and increase the stability of the biologically active conformation of p53 mutants, including p53 Y220C, to restore DNA binding and downstream tumor-suppressive activity. Disclosed embodiments include substituted indole-alkynyl aniline compounds, retrospective confirmation of mutations, copy-number variant assessments, and companion-diagnostic concepts. The background section is omitted from the provided content, so the underlying problem addressed is not explicitly described in patent.
Claims Coverage
The provided claims identify one independent claim comprising three inventive features.
Treatment of cancer having a p53-deactivating TP53 mutation
The claim element recites a method of treating a subject suffering from cancer having a p53-deactivating mutation in a TP53 gene that encodes a p53 mutant protein.
Prior determination of the mutation in a biological sample
The claim element requires that the subject has previously been determined to have the p53-deactivating mutation in the TP53 gene based on an assay performed on a biological sample of the subject.
Administration of specified compounds or salts
The claim element recites administering a therapeutically effective amount of a compound selected from 4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide; N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine; or N-[(2S)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide, or a pharmaceutically acceptable salt thereof.
The independent claim combines prior assay-based determination of a p53-deactivating TP53 mutation in a biological sample with administration of one of three specified compounds or a pharmaceutically acceptable salt to treat the associated cancer.
Stated Advantages
The compounds stabilize mutant p53, including p53 Y220C, and restore DNA binding and downstream tumor-suppressive activity.
Proposed effects of mutant p53 reactivation include apoptosis, cell-cycle arrest, senescence, and reduced cancer progression.
Documented Applications
Treatment of a subject suffering from cancer having an assay-confirmed p53-deactivating mutation in a TP53 gene, including p53 Y220C and lung cancer, using one of the specified compounds or a pharmaceutically acceptable salt.
Companion-diagnostic concepts for determining TP53 mutation status from a biological sample.
Interested in licensing this patent?